Target Validation Information
TTD ID	T21334
Target Name	Osteoclast differentiation factor (ODF)
Type of Target	Successful
Drug Potency against Target	Denosumab	Drug Info	IC50 < 1 nM	[2]
Action against Disease Model	Denosumab	Drug Info	Denos uMab and h uMan OPG-Fc inhibited the ability of h uMan RANKL (143-317) to stimulate the formation of osteoclasts derived from murine RAW 264.7 cells, with IC50 values of 1.64 and 1.15 nM, respectively.	[1]
References
REF 1	CCK1 receptor antagonist, dexloxiglumide: effects on human isolated gallbladder. Potential clinical applications. Minerva Gastroenterol Dietol. 2003 Sep;49(3):211-6.
REF 2	Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2009 Feb;24(2):182-95.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.